propafenone has been researched along with Ventricular Fibrillation in 37 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of a 43 year old man who was diagnosed with Brugada syndrome after propafenone administration for chemical cardioversion of new onset atrial fibrillation." | 7.73 | Brugada syndrome, manifested by propafenone induced ST segment elevation. ( Aksay, E; Okan, T; Yanturali, S, 2005) |
| "The effects of propafenone (Pro), a new Ic anti-arrhythmic agent (AAA), quinidine (Qui), and their combination on ventricular fibrillation threshold (VFT) and other electrophysiological properties were evaluated in 20 dogs." | 7.68 | [Effects of propafenone, quinidine, and their combination on ventricular fibrillation threshold in dogs]. ( Lu, F; Mei, BY; Zhang, XM, 1992) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 7.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 7.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "Propafenone was administered to 29 patients who had multiple episodes of recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) despite previous antiarrhythmic therapy." | 7.67 | Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. ( Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "The electrophysiological effects of lidocaine (L) and propafenone (P) in chronic myocardial infarction in relation to tissue drug concentrations (TDC) are unknown." | 7.67 | Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations. ( Agarwal, JB; Bracchetti, D; Helfant, RH; Naccarella, FF; Weintraub, WS, 1984) |
| "During treatment with the class Ic antiarrhythmic agent propafenone, the drug appeared to cause malignant ventricular tachyarrhythmias in five patients." | 7.67 | Malignant ventricular tachyarrhythmias in association with propafenone treatment. ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "Lidocaine is most widely used for suppression of recurrent ventricular tachyarrhythmias by IV application." | 7.66 | [Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)]. ( Glogar, D; Laimer, H; Zilcher, H, 1981) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 6.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 5.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Propafenone is an antiarrhythmic agent with fast sodium channel, calcium channel, and beta-adrenergic receptor blocking properties." | 5.28 | Effects of propafenone on pacing-induced ventricular fibrillation and intracellular calcium in rat hearts. ( Parmley, WW; Stefenelli, T; Wikman-Coffelt, J; Wu, ST, 1992) |
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 5.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| " In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation." | 5.07 | Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. ( Cappato, R; Kuck, KH; Rüppel, R; Schneider, MA; Siebels, J, 1993) |
| "We report a case of a 43 year old man who was diagnosed with Brugada syndrome after propafenone administration for chemical cardioversion of new onset atrial fibrillation." | 3.73 | Brugada syndrome, manifested by propafenone induced ST segment elevation. ( Aksay, E; Okan, T; Yanturali, S, 2005) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 3.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 3.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "Propafenone, a new antiarrhythmic drug, was administered to 60 patients with a history of refractory ventricular tachyarrhythmias, including ventricular fibrillation in 16 and ventricular tachycardia (VT) in 44." | 3.67 | Propafenone: noninvasive evaluation of efficacy. ( Cytryn, R; Lown, B; Podrid, PJ, 1984) |
| "Propafenone was administered to 29 patients who had multiple episodes of recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) despite previous antiarrhythmic therapy." | 3.67 | Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. ( Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "The electrophysiological effects of lidocaine (L) and propafenone (P) in chronic myocardial infarction in relation to tissue drug concentrations (TDC) are unknown." | 3.67 | Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations. ( Agarwal, JB; Bracchetti, D; Helfant, RH; Naccarella, FF; Weintraub, WS, 1984) |
| "During treatment with the class Ic antiarrhythmic agent propafenone, the drug appeared to cause malignant ventricular tachyarrhythmias in five patients." | 3.67 | Malignant ventricular tachyarrhythmias in association with propafenone treatment. ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "Lidocaine is most widely used for suppression of recurrent ventricular tachyarrhythmias by IV application." | 3.66 | [Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)]. ( Glogar, D; Laimer, H; Zilcher, H, 1981) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 2.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| "In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, multicenter, randomized controlled study, was started in survivors of sudden cardiac death resulting from documented ventricular tachyarrhythmias." | 2.67 | Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). ( Kuck, KH; Siebels, J, 1994) |
| "Propafenone toxicity can cause significant QRS widening and markedly abnormal ventricular activation pattern." | 1.34 | Cardiac memory induced by QRS widening due to propafenone toxicity. ( Josephson, ME; Shvilkin, A; Wylie, JV; Zimetbaum, P, 2007) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 1.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Propafenone is a new drug that has been shown to be efficacious in the therapy of supraventricular and ventricular arrhythmias, and is of potential use in patients with defibrillators." | 1.28 | Effects of acute and prolonged administration of propafenone on internal defibrillation in the pig. ( Barilaro, C; Bombardieri, G; Jones, DL; Kim, YH; Klein, GJ; Montenero, AS; Natale, A, 1992) |
| "Propafenone 2 mg/kg was injected intravenously in 21 dogs." | 1.28 | [Correlation of signal-averaged electrocardiograms with the threatening ventricular arrhythmia during recovery period of experimental acute myocardial infarction]. ( Zha, Y, 1991) |
| " The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing." | 1.27 | [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation]. ( Delise, P; Di Pede, F; Piccolo, E; Raviele, A, 1984) |
| "Diprafenone (D) is a new class I c antiarrhythmic agent, structurally similar to propafenone." | 1.27 | Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction. ( Bender, F; Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 1.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.03) | 18.7374 |
| 1990's | 22 (59.46) | 18.2507 |
| 2000's | 5 (13.51) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aksay, E | 1 |
| Okan, T | 1 |
| Yanturali, S | 1 |
| Hasdemir, C | 1 |
| Olukman, M | 1 |
| Ulucan, C | 1 |
| Roden, DM | 1 |
| Wylie, JV | 1 |
| Zimetbaum, P | 1 |
| Josephson, ME | 1 |
| Shvilkin, A | 1 |
| Jastrzebski, M | 1 |
| Podrid, PJ | 1 |
| Cytryn, R | 1 |
| Lown, B | 1 |
| Heger, JJ | 1 |
| Hubbard, J | 1 |
| Zipes, DP | 1 |
| Miles, WM | 1 |
| Prystowsky, EN | 1 |
| Raviele, A | 1 |
| Di Pede, F | 1 |
| Delise, P | 1 |
| Piccolo, E | 1 |
| Naccarella, FF | 1 |
| Agarwal, JB | 1 |
| Weintraub, WS | 1 |
| Bracchetti, D | 1 |
| Helfant, RH | 1 |
| Ruipérez Abizanda, JA | 1 |
| Campos Peris, JV | 1 |
| Ruiz Ros, JA | 1 |
| García García, J | 1 |
| Jaen Armand, E | 1 |
| Marco Quiles, J | 1 |
| Martínez Jerez, M | 1 |
| Salas Nieto, J | 1 |
| Rodríguez Ruiz, P | 1 |
| Pico Aracil, F | 1 |
| Laimer, H | 1 |
| Glogar, D | 1 |
| Zilcher, H | 1 |
| Siebels, J | 3 |
| Cappato, R | 2 |
| Rüppel, R | 2 |
| Schneider, MA | 2 |
| Kuck, KH | 3 |
| Bellone, P | 1 |
| Spirito, P | 1 |
| Vecchio, C | 1 |
| Eggenreich, U | 1 |
| Fleischmann, PH | 1 |
| Stark, G | 1 |
| Wach, P | 1 |
| Stevens, SK | 1 |
| Haffajee, CI | 1 |
| Naccarelli, GV | 1 |
| Schwartz, KM | 1 |
| Luceri, RM | 1 |
| Packer, DL | 1 |
| Rubin, AM | 1 |
| Kowey, PR | 2 |
| Botto, GL | 1 |
| Bonini, W | 1 |
| Broffoni, T | 1 |
| Molteni, S | 1 |
| Lombardi, R | 1 |
| Alfieri, G | 1 |
| Barone, P | 1 |
| Bernasconi, G | 1 |
| Ferrari, G | 1 |
| Dabrowski, R | 1 |
| Skrabucha, B | 1 |
| Kunicki, PK | 1 |
| Kowalik, I | 1 |
| Skorykow-Sapińska, A | 1 |
| Sitkiewicz, D | 1 |
| Sadowski, Z | 1 |
| Qiu, HY | 1 |
| Li, DJ | 1 |
| Mao, HY | 1 |
| Matana, A | 1 |
| Goldner, V | 1 |
| Stanić, K | 1 |
| Mavrić, Z | 1 |
| Zaputović, L | 1 |
| Matana, Z | 1 |
| Lombardi, F | 2 |
| Torzillo, D | 2 |
| Sandrone, G | 2 |
| Dalla Vecchia, L | 2 |
| Cappiello, E | 2 |
| Stefenelli, T | 1 |
| Wu, ST | 1 |
| Parmley, WW | 1 |
| Wikman-Coffelt, J | 1 |
| Finocchiaro, ML | 1 |
| Bernasconi, R | 1 |
| Lu, F | 1 |
| Zhang, XM | 1 |
| Mei, BY | 1 |
| Nakamura, T | 1 |
| Kashimoto, S | 1 |
| Oguchi, T | 1 |
| Kumazawa, T | 1 |
| Natale, A | 1 |
| Montenero, AS | 2 |
| Bombardieri, G | 2 |
| Barilaro, C | 2 |
| Kim, YH | 1 |
| Klein, GJ | 1 |
| Jones, DL | 1 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Marshall, RJ | 1 |
| Muir, AW | 1 |
| Zha, Y | 1 |
| Podczeck, A | 1 |
| Frohner, K | 1 |
| Hief, C | 1 |
| Stix, G | 1 |
| Steinbach, KK | 1 |
| Timour, Q | 1 |
| Aupetit, JF | 1 |
| Loufoua-Moundanga, J | 1 |
| Gerentes-Chassagne, I | 1 |
| Kioueh, I | 1 |
| Faucon, G | 1 |
| Peters, W | 1 |
| Gang, ES | 1 |
| Okazaki, H | 1 |
| Solingen, S | 1 |
| Kobayashi, Y | 1 |
| Karagueuzian, HS | 1 |
| Mandel, WJ | 1 |
| Stohler, JL | 1 |
| Friehling, TD | 1 |
| Marinchak, RA | 1 |
| Di Francesco, P | 1 |
| Santarelli, P | 1 |
| Calvi, V | 1 |
| Schiavello, R | 1 |
| Alessandrini, F | 1 |
| Pisanò, E | 1 |
| Salsano, M | 1 |
| Grubb, BP | 1 |
| Thale, J | 1 |
| Gülker, H | 1 |
| Hindricks, G | 1 |
| Haverkamp, W | 1 |
| Bender, F | 1 |
| Buss, J | 1 |
| Neuss, H | 1 |
| Bilgin, Y | 1 |
| Schlepper, M | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Abate, D | 1 |
| Henry, WL | 1 |
1 review available for propafenone and Ventricular Fibrillation
| Article | Year |
|---|---|
Propafenone--a new agent for the treatment of ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Humans; Propafenone; Ventricular Fibrillation | 1989 |
8 trials available for propafenone and Ventricular Fibrillation
| Article | Year |
|---|---|
[Propafenone, a new anti arrhythmic agent].
Topics: Anesthetics, Local; Anti-Arrhythmia Agents; Clinical Trials as Topic; Drug Evaluation; Female; Human | 1980 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Hea | 1994 |
Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Defibrillators, Impl | 1996 |
Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?
Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Atr | 1996 |
[Evaluation of the rate for reaching steady state during oral propafenone therapy in patients with ventricular arrhythmias].
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Drug Administration Schedule; Electrocardiograph | 1998 |
Propafenone in the treatment of patients with malignant ventricular tachyarrhythmias.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Propafenone; Tachycardia; Ventricular Fi | 1991 |
28 other studies available for propafenone and Ventricular Fibrillation
| Article | Year |
|---|---|
Brugada syndrome, manifested by propafenone induced ST segment elevation.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Humans; Male; Propafenone; | 2005 |
Brugada-type ECG pattern and extreme QRS complex widening with propafenone overdose.
Topics: Adolescent; Bundle-Branch Block; Drug Overdose; Electrocardiography; Female; Heart Conduction System | 2006 |
Cardiac memory induced by QRS widening due to propafenone toxicity.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Propafenone; Ventricular Fibrilla | 2007 |
[Ventricular fibrillation and Brugada-like ECG pattern during propafenone treatment].
Topics: Aged; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Humans; Male; Propafenone; Vent | 2008 |
Propafenone: noninvasive evaluation of efficacy.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Drug Evaluation; Electrocardiography; Exercise Test | 1984 |
Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Female; Humans | 1984 |
[Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
Topics: Adult; Aged; Amiodarone; Death, Sudden; Disopyramide; Drug Therapy, Combination; Electrocardiography | 1984 |
Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbon Radioisotopes; Coronary Circulation; D | 1984 |
[Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)].
Topics: Administration, Oral; Adolescent; Adult; Aged; Drug Evaluation; Drug Resistance; Female; Heart Ventr | 1981 |
Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone.
Topics: Amiodarone; Electric Countershock; Humans; Injections, Intravenous; Lidocaine; Male; Middle Aged; My | 1994 |
Effects of propafenone on the median frequency of ventricular fibrillation in Langendorff perfused guinea-pig hearts.
Topics: Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Electrocardiography; Female; Guin | 1996 |
[Effects of propafenone on electrophysiologic changes caused by alteration of left ventricular afterload in anesthetized rabbits].
Topics: Animals; Anti-Arrhythmia Agents; Propafenone; Rabbits; Refractory Period, Electrophysiological; Vent | 1997 |
Unmasking effect of propafenone on the concealed form of the Brugada phenomenon.
Topics: Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Female; Humans; Middle Aged; Propa | 2000 |
Autonomic effects of antiarrhythmic drugs and their importance.
Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini | 1992 |
Effects of propafenone on pacing-induced ventricular fibrillation and intracellular calcium in rat hearts.
Topics: Animals; Calcium; Calcium Channel Blockers; Cardiac Pacing, Artificial; Dose-Response Relationship, | 1992 |
Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Heart Rate; Humans; Posture; Propafenone; Receptor | 1992 |
[Effects of propafenone, quinidine, and their combination on ventricular fibrillation threshold in dogs].
Topics: Animals; Blood Pressure; Dogs; Drug Therapy, Combination; Female; Male; Propafenone; Quinidine; Vent | 1992 |
Effects of propafenone on function and metabolism in the ischemic working rat heart.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Energy Metabolism; Heart Rate; Hemodynamics; Male; | 1992 |
Effects of acute and prolonged administration of propafenone on internal defibrillation in the pig.
Topics: Animals; Electric Conductivity; Electric Countershock; Electrocardiography; Electrodes, Implanted; P | 1992 |
Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Estrenes; Female; | 1991 |
[Correlation of signal-averaged electrocardiograms with the threatening ventricular arrhythmia during recovery period of experimental acute myocardial infarction].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Electrocardiography; Heart Ventricles; My | 1991 |
Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Disease; Drug Evaluation; Electric St | 1991 |
Class Ic antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Disease; Coronary Vesse | 1991 |
Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog.
Topics: Animals; Combined Modality Therapy; Dogs; Electric Countershock; Electrocardiography; Female; Infusi | 1991 |
Intravenous propafenone reduces energy requirements for defibrillation in pigs.
Topics: Animals; Carbon Dioxide; Electric Countershock; Electrocardiography; Electrolytes; Hydrogen-Ion Conc | 1990 |
Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Chemical Phenomena; Chemis | 1987 |
Malignant ventricular tachyarrhythmias in association with propafenone treatment.
Topics: Adult; Aged; Arrhythmias, Cardiac; Death, Sudden; Electrocardiography; Humans; Male; Middle Aged; Pr | 1985 |
Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrophysiology; E | 1985 |